Literature DB >> 23884073

Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.

Jens Reimer1, Christiane Sybille Schmidt, Bernd Schulte, Dirk Gansefort, Jörg Gölz, Guido Gerken, Norbert Scherbaum, Uwe Verthein, Markus Backmund.   

Abstract

BACKGROUND: People who inject drugs (PWID) have a high prevalence of hepatitis C virus (HCV) infection. However, PWID are considered "difficult to treat," requiring a specifically adapted treatment setting, including psychosocial support.
METHODS: In this prospective, German trial, the impact of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy among PWID was evaluated. We included 198 patients in opiate substitution therapy, who fulfilled indications for antiviral treatment. All patients received pegylated interferon alfa-2a and ribavirin therapy. Patients in the intervention group (n = 82) received manualized PE sessions.
RESULTS: In patients with HCV genotype 1 or 4 (GT 1/4), PE was associated with increased treatment completion (76% vs 55%, P = .038), whereas PE had no such effect among GT 2/3 patients, who showed fewer dropouts and higher SVR rates. Among GT 1/4 patients, a minimum of 5 PE sessions was associated with increased SVR (71% vs 48%, P = .037). Multivariate regression analyses confirmed the impact of PE in GT 1/4 and revealed further predictors for retention and SVR, such as preexisting mental distress and adverse events.
CONCLUSIONS: In patients with a higher risk of dropout due to GT 1/4 or mental distress, PE was shown to improve retention and SVR. PE is an effective supportive intervention for HCV therapy among PWID.

Entities:  

Keywords:  antiviral treatment; hepatitis C; injection drug users; psychoeducation; retention

Mesh:

Substances:

Year:  2013        PMID: 23884073     DOI: 10.1093/cid/cit307

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

4.  Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study.

Authors:  Bernd Schulte; Christiane S Schmidt; Jakob Manthey; Lisa Strada; Stefan Christensen; Konrad Cimander; Herbert Görne; Pavel Khaykin; Norbert Scherbaum; Stefan Walcher; Stefan Mauss; Ingo Schäfer; Uwe Verthein; Jürgen Rehm; Jens Reimer
Journal:  Open Forum Infect Dis       Date:  2020-08-13       Impact factor: 3.835

Review 5.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

6.  Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.

Authors:  Christer F Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Aaron G Lim; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-06-30

7.  Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Authors:  Christoph Höner Zu Siederdissen; Peter Buggisch; Klaus Böker; Eckart Schott; Hartwig Klinker; Anita Pathil; Heike Pfeiffer-Vornkahl; Thomas Berg; Christoph Sarrazin; Dietrich Hüppe; Michael P Manns; Stefan Mauss
Journal:  United European Gastroenterol J       Date:  2017-06-17       Impact factor: 4.623

8.  Hepatitis C virus prevention and care for drug injectors: the French approach.

Authors:  Jean-Michel Delile; Victor de Ledinghen; Marie Jauffret-Roustide; Perrine Roux; Brigitte Reiller; Juliette Foucher; Daniel Dhumeaux
Journal:  Hepatol Med Policy       Date:  2018-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.